Y-Mabs Therapeutics Inc (NASDAQ: YMAB) is 125.66% higher on its value in year-to-date trading and has touched a low of $4.69 and a high of $20.90 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The YMAB stock was last observed hovering at around $15.17 in the last trading session, with the day’s gains setting it 0.22%.
Currently trading at $15.39, the stock is 25.52% and 26.93% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.91 million and changing 1.45% at the moment leaves the stock 29.02% off its SMA200. YMAB registered 182.39% gain for a year compared to 6-month loss of -5.76%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 29.33% gain in the last 1 month and extending the period to 3 months gives it a 25.43%, and is 11.12% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.65% over the week and 7.72% over the month.
Y-Mabs Therapeutics Inc (YMAB) has around 100 employees, a market worth around $685.93M and $86.55M in sales. Profit margin for the company is -28.44%. Distance from 52-week low is 228.14% and -26.36% from its 52-week high. The company has generated returns on investments over the last 12 months (-25.70%).
with sales reaching $23.81M over the same period.The EPS is expected to shrink by -25.62% this year, but quarterly earnings will post 8.80% year-over-year. Quarterly sales are estimated to grow 16.40% in year-over-year returns.
150.0 institutions hold shares in Y-Mabs Therapeutics Inc (YMAB), with institutional investors hold 79.02% of the company’s shares. The shares outstanding are 43.67M, and float is at 36.80M with Short Float at 13.05%. Institutions hold 69.37% of the Float.
The top institutional shareholder in the company is PARADIGM BIOCAPITAL ADVISORS LP with over 3.87 million shares valued at $46.76 million. The investor’s holdings represent 8.8411 of the YMAB Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 2.94 million shares valued at $35.5 million to account for 6.7126 of the shares outstanding. The other top investors are SOFINNOVA INVESTMENTS, INC. which holds 2.19 million shares representing 5.0121 and valued at over $26.51 million, while VANGUARD GROUP INC holds 4.4709 of the shares totaling 1.96 million with a market value of $23.64 million.
Y-Mabs Therapeutics Inc (YMAB) Insider Activity
Y-Mabs Therapeutics Inc disclosed in a document filed with the SEC on Aug 26 ’24 that Wilms Joris (SVP & CHIEF OPERATING OFFICER) sold a total of 5,000 shares of the company’s common stock. The trade occurred on Aug 26 ’24 and was made at $14.69 per share for $73450.0. Following the transaction, the insider now directly holds 30600.0 shares of the YMAB stock.
Still, SEC filings show that on Aug 26 ’24, Wilms Joris (Officer) Proposed Sale 5,000 shares at an average price of $14.69 for $73450.0. The insider now directly holds shares of Y-Mabs Therapeutics Inc (YMAB).
